Sign In
Buy ASND
$243.91
-7.16 (-2.85%)
At Close: Jul 31, 2026
Ascendis Pharma A/S Reports Full-Year 2019 Financial Results
08:01pm, Wednesday, 01'st Apr 2020
– On track with 2020 corporate milestones – – Top-line data from PaTH Forward phase 2 trial on track for mid-April – – Conference call today...
Afternoon Market Stats in 5 Minutes
04:51pm, Wednesday, 01'st Apr 2020
Movers Indices • S&P 500 ETF (NYSE:SPY) fell 3.16% to $249.22.• Nasdaq ETF (NASDAQ:QQQ) decreased 2.27% to $186.07.• Dow Jones Industrial Average ETF (NYSE:DIA) fell 2.92% to $212.74.• FTSE/Xi
Morning Market Stats in 5 Minutes
02:46pm, Wednesday, 01'st Apr 2020
Movers Indices • S&P 500 ETF (NYSE:SPY) decreased 3.65% to $247.96.• Nasdaq ETF (NASDAQ:QQQ) fell 2.93% to $184.83.• Dow Jones Industrial Average ETF (NYSE:DIA) fell 3.99% to $210.41.• FTSE/Xi
The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests
11:38am, Wednesday, 01'st Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 31) * Athersys Inc (NASDAQ: ATHX) * Forty Seven Inc (NA
Ascendis Pharma A/S (NASDAQ:ASND) Stock Rating Upgraded by Zacks Investment Research
09:42am, Wednesday, 01'st Apr 2020
Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Monday, Zacks.com reports. The firm presently
Earnings Scheduled For April 1, 2020
08:39am, Wednesday, 01'st Apr 2020
Companies Reporting Before The Bell
UniFirst Corporation (NYSE: UNF) is estimated to report quarterly earnings at $1.65 per share on revenue of $457.48 million.
Lamb Weston...
Ascendis Pharma options imply 12.5% move in share price post-earnings ASND
08:19am, Wednesday, 01'st Apr 2020
Ascendis Pharma options imply 12.5% move in share price post-earnings ASND
Sofinnova Investments Strengthens Executive Team with Promotions of Maha Katabi, PhD, CFA and Sarah Bhagat, PhD
01:00pm, Tuesday, 31'st Mar 2020
Sofinnova Investments announces the promotions of Maha Katabi and Sarah Bhagat.
Ascendis Pharma price target raised to $166 from $144 at Canaccord ASND
11:46am, Tuesday, 31'st Mar 2020
Ascendis Pharma price target raised to $166 from $144 at Canaccord Canaccord ASND
Ascendis Pharma (ASND) Gets a Buy Rating from Canaccord Genuity
10:09am, Tuesday, 31'st Mar 2020
In a report released today, Michelle Gilson from Canaccord Genuity maintained a Buy rating on Ascendis Pharma (ASND), with a price target of $166.00. The
Ascendis Pharma (ASND) Gets a Buy Rating from Canaccord Genuity
10:09am, Tuesday, 31'st Mar 2020
In a report released today, Michelle Gilson from Canaccord Genuity maintained a Buy rating on Ascendis Pharma (ASND – Research
Ascendis Pharma A/S (ASND) Scheduled to Post Earnings on Wednesday
05:54am, Tuesday, 31'st Mar 2020
Ascendis Pharma A/S (NASDAQ:ASND) is scheduled to release its earnings data after the market closes on Wednesday, April 1st. Analysts expect Ascendis Pharma A/S to post earnings of ($1.27) per share f
Ascendis Pharma A/S (NASDAQ:ASND) Receives "Buy" Rating from Bank of America
06:00am, Monday, 30'th Mar 2020
Bank of America reissued their buy rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report report published on Friday morning, AnalystRatings.com reports. They currently have a $145
Comparing Ascendis Pharma A/S (NASDAQ:ASND) and Zosano Pharma (NASDAQ:ZSAN)
09:44am, Sunday, 29'th Mar 2020
Ascendis Pharma A/S (NASDAQ:ASND) and Zosano Pharma (NASDAQ:ZSAN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valua
Alliancebernstein L.P. Buys 1,940 Shares of Ascendis Pharma A/S (NASDAQ:ASND)
08:46am, Sunday, 29'th Mar 2020
Alliancebernstein L.P. lifted its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 0.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutiona
